Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more
Biotest Aktiengesellschaft (BIESF) - Net Assets
Latest net assets as of March 2025: $509.60 Million USD
Based on the latest financial reports, Biotest Aktiengesellschaft (BIESF) has net assets worth $509.60 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.42 Billion) and total liabilities ($906.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $509.60 Million |
| % of Total Assets | 35.98% |
| Annual Growth Rate | 7.38% |
| 5-Year Change | 20.18% |
| 10-Year Change | 28.72% |
| Growth Volatility | 26.99 |
Biotest Aktiengesellschaft - Net Assets Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual net assets of Biotest Aktiengesellschaft from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $530.70 Million | +6.37% |
| 2023-12-31 | $498.90 Million | +34.44% |
| 2022-12-31 | $371.10 Million | -2.44% |
| 2021-12-31 | $380.40 Million | -13.86% |
| 2020-12-31 | $441.60 Million | -7.40% |
| 2019-12-31 | $476.90 Million | -3.70% |
| 2018-12-31 | $495.20 Million | +42.38% |
| 2017-12-31 | $347.80 Million | -3.58% |
| 2016-12-31 | $360.70 Million | -12.52% |
| 2015-12-31 | $412.30 Million | -14.14% |
| 2014-12-31 | $480.20 Million | +4.23% |
| 2013-12-31 | $460.70 Million | +24.70% |
| 2012-12-31 | $369.43 Million | +6.57% |
| 2011-12-31 | $346.67 Million | +12.70% |
| 2010-12-31 | $307.61 Million | +13.99% |
| 2009-12-31 | $269.86 Million | +6.51% |
| 2008-12-31 | $253.37 Million | +12.23% |
| 2007-12-31 | $225.76 Million | +109.10% |
| 2004-12-31 | $107.97 Million | +4.53% |
| 2003-12-31 | $103.29 Million | -6.78% |
| 2002-12-31 | $110.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotest Aktiengesellschaft's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27450000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $274.50 Million | 51.72% |
| Common Stock | $39.60 Million | 7.46% |
| Other Components | $216.60 Million | 40.81% |
| Total Equity | $530.70 Million | 100.00% |
Biotest Aktiengesellschaft Competitors by Market Cap
The table below lists competitors of Biotest Aktiengesellschaft ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Collins Foods Limited
PINK:CLLFF
|
$640.38 Million |
|
Edifier Technology Co Ltd
SHE:002351
|
$640.66 Million |
|
Shanghai SK Automation Technology Co. Ltd. A
SHG:688155
|
$641.08 Million |
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
$641.27 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
$640.32 Million |
|
Cyfrowy Polsat S.A
OTCGREY:CYFWF
|
$640.25 Million |
|
Weis Markets Inc
NYSE:WMK
|
$639.66 Million |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
$639.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotest Aktiengesellschaft's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 498,900,000 to 530,700,000, a change of 31,800,000 (6.4%).
- Net income of 26,400,000 contributed positively to equity growth.
- Dividend payments of 1,600,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,100,000.
- Other factors increased equity by 8,100,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $26.40 Million | +4.97% |
| Dividends Paid | $1.60 Million | -0.3% |
| Other Comprehensive Income | $-1.10 Million | -0.21% |
| Other Changes | $8.10 Million | +1.53% |
| Total Change | $- | 6.37% |
Book Value vs Market Value Analysis
This analysis compares Biotest Aktiengesellschaft's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.23x to 2.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $4.43 | $32.00 | x |
| 2003-12-31 | $4.18 | $32.00 | x |
| 2004-12-31 | $4.34 | $32.00 | x |
| 2005-12-31 | $6.33 | $32.00 | x |
| 2006-12-31 | $5.52 | $32.00 | x |
| 2007-12-31 | $6.78 | $32.00 | x |
| 2008-12-31 | $7.07 | $32.00 | x |
| 2009-12-31 | $7.52 | $32.00 | x |
| 2010-12-31 | $8.57 | $32.00 | x |
| 2011-12-31 | $9.85 | $32.00 | x |
| 2012-12-31 | $10.50 | $32.00 | x |
| 2013-12-31 | $12.32 | $32.00 | x |
| 2014-12-31 | $12.13 | $32.00 | x |
| 2015-12-31 | $10.42 | $32.00 | x |
| 2016-12-31 | $9.11 | $32.00 | x |
| 2017-12-31 | $8.78 | $32.00 | x |
| 2018-12-31 | $12.51 | $32.00 | x |
| 2019-12-31 | $12.05 | $32.00 | x |
| 2020-12-31 | $11.16 | $32.00 | x |
| 2021-12-31 | $9.61 | $32.00 | x |
| 2022-12-31 | $9.38 | $32.00 | x |
| 2023-12-31 | $12.61 | $32.00 | x |
| 2024-12-31 | $13.41 | $32.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotest Aktiengesellschaft utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.64%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 2.70x
- Recent ROE (4.97%) is above the historical average (4.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 18.64% | 7.68% | 0.69x | 3.50x | $9.18 Million |
| 2003 | -5.22% | -2.36% | 0.63x | 3.49x | $-15.29 Million |
| 2004 | 5.62% | 2.69% | 0.61x | 3.44x | $-4.55 Million |
| 2007 | 7.77% | 5.29% | 0.61x | 2.41x | $-4.97 Million |
| 2008 | 11.30% | 7.29% | 0.65x | 2.38x | $3.23 Million |
| 2009 | 10.58% | 7.18% | 0.62x | 2.39x | $1.54 Million |
| 2010 | 13.09% | 9.57% | 0.65x | 2.10x | $9.33 Million |
| 2011 | 13.37% | 10.98% | 0.62x | 1.97x | $11.70 Million |
| 2012 | 9.05% | 7.59% | 0.64x | 1.85x | $-3.52 Million |
| 2013 | 6.95% | 6.39% | 0.56x | 1.92x | $-14.06 Million |
| 2014 | 4.00% | 3.30% | 0.56x | 2.15x | $-28.81 Million |
| 2015 | -20.01% | -13.99% | 0.61x | 2.34x | $-123.72 Million |
| 2016 | -12.70% | -8.28% | 0.59x | 2.59x | $-81.85 Million |
| 2017 | -1.01% | -0.93% | 0.39x | 2.82x | $-38.26 Million |
| 2018 | 36.63% | 45.29% | 0.38x | 2.11x | $131.80 Million |
| 2019 | -0.99% | -1.12% | 0.38x | 2.32x | $-52.39 Million |
| 2020 | -7.11% | -6.48% | 0.43x | 2.56x | $-75.56 Million |
| 2021 | -16.67% | -12.30% | 0.47x | 2.90x | $-101.44 Million |
| 2022 | -8.54% | -6.14% | 0.43x | 3.24x | $-68.81 Million |
| 2023 | 25.46% | 18.55% | 0.49x | 2.83x | $77.11 Million |
| 2024 | 4.97% | 3.64% | 0.51x | 2.70x | $-26.67 Million |
Industry Comparison
This section compares Biotest Aktiengesellschaft's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotest Aktiengesellschaft (BIESF) | $509.60 Million | 18.64% | 1.78x | $640.35 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |